A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Relapsed or Refractory Diffuse Large B-cell Lymphoma Clinical Trial

Official title:
A Phase 1, Multi-center, Open-label, Uncontrolled, Dose-escalation Trial to Evaluate the Safety of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Status Active, not recruiting

Clinical Trial Summary

To investigate the tolerability and safety of OPB-111077 in combination with bendamustine and rituximab in patients with r/r DLBCL.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Relapsed or Refractory Diffuse Large B-cell Lymphoma

Clinical Trial Details

NCT number	NCT04049825
Study type	Interventional
Source	Otsuka Pharmaceutical Co., Ltd.
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	November 22, 2019
Completion date	March 2025

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04279938` - A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL	Phase 1
Suspended	`NCT04607772` - Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 1/Phase 2
Active, not recruiting	`NCT06074107` - Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects	Phase 2
Active, not recruiting	`NCT05144841` - A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)	Phase 2